Post-trial follow-up | Nivolumab plus ipilimumab vs. chemotherapy as first-line treatment for metastatic non-small cell lung cancer.

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227 – Journal of Clinical Oncology (link to abstract – $ for full-text)

Original Study: #ESMO19 –Randomized Trial: Improved Overall Survival with Combined Immunotherapy for Advanced Non–Small-Cell Lung Cancer